The Bezerra Lab current studies investigate how developmental defects increase the susceptibility of the biliary epithelium to infectious and toxic insults.

Our lab is studying novel regulatory mechanisms that control innate immunity in intestinal health and disease.

We aim to elucidate the role of the innate immune system in damage and repair following ischemic and hemorrhagic insults to the brain. We are specifically focused on innate immune drivers of secondary injury following aneurysmal subarachnoid hemorrhage and the immune response triggered by acute intracranial pressure spikes during aneurysm rupture. We also look into promoting recovery after ischemic stroke by reprogramming microglia and peripheral myeloid cells to drive repair. In addition, we are pursuing the development of therapeutics for intraarterial immunomodulation for chronic subdural hemorrhage.

The Farrar Lab is interested in understanding how external signals regulate immune cell function and development. 

The Robertson Lab studies mitochondrial and metabolic homeostasis in the corneal epithelium and the role of homeostatic dysfunction in the pathophysiology of corneal disease.

Our lab studies the fundamental mechanisms of how commensal fungi survive and persist within a host niche filled with a multitude of innate and adaptive immune effectors, under both homeostatic and inflammatory conditions. We aim for our study to provide unique insights into human diseases, such as asthma, inflammatory bowel disease, and cancer, and provides the foundation for novel immunotherapeutic approaches.

The Nair-Gill Lab dissects the cellular infrastructure that dictates immune cell survival and fate decisions.

The Monson Lab is dedicated to understanding how B cells and T cells impact pathology of disease in the central nervous system.

Kong lab aims to harness the cutting-edge technologies in human genetics and genomics, immunology, and molecular biology to better understand the pathogenesis of gastrointestinal inflammation.

Qiao lab focuses on mechanisms of cancer immunotherapy and immune-related adverse events (irAEs)